Egetis Therapeutics AB (publ)

Stockholm Stock Exchange EGTX.ST

Egetis Therapeutics AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: -49.17%

Egetis Therapeutics AB (publ) Return on Capital Employed (ROCE) is -49.17% for the year ending December 31, 2023, a -29.89% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Egetis Therapeutics AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -37.85%, a -92.29% change year over year.
Egetis Therapeutics AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -19.69%, a 8.90% change year over year.
Egetis Therapeutics AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -21.61%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: EGTX.ST

Egetis Therapeutics AB (publ)

CEO	Mr. Nicklas Westerholm
IPO Date	April 7, 2011
Location	Sweden
Headquarters	Klara Norra Kyrkogata 26
Employees	28
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Key trends

Past 5 years